TY - JOUR
T1 - DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM
AU - Mccracken, GeorgeH
AU - Dowell, DuaneL
AU - Marshall, FlorenceN
N1 - Funding Information:
no and significant days of gavage difference feeding for between the survivors, 10,000 there units wasof T.A.T. and 500 units of T.I.G. in the treatment of neo- natal tetanus. This is the first controlled study demonstrating the comparability of these two antisera in tetanus neonatorum. Trials with different doses of T.I.G. are in progress. We thank Dr. and Mrs. Larimer Mellon for allowing this study at the H6pital Albert Schweitzer and Dr. Frank J. LePreau for his helpful advice and support. This work was done with the technical assistance of Susan G. Mize. The study was supported in part by Lederle Laboratories, Pearl River, New York. Requests for reprints should be addressed to M., 5323 Harry Hines Blvd, Dallas, Texas 75235, U.S.A.
PY - 1971/6/5
Y1 - 1971/6/5
N2 - 130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.
AB - 130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.
UR - http://www.scopus.com/inward/record.url?scp=0015211628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015211628&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(71)91659-X
DO - 10.1016/S0140-6736(71)91659-X
M3 - Article
C2 - 4102858
AN - SCOPUS:0015211628
SN - 0140-6736
VL - 297
SP - 1146
EP - 1149
JO - The Lancet
JF - The Lancet
IS - 7710
ER -